Inmagene (创响生物) is a biotechnology company focused on developing immunology drugs. Its pipeline is driven by a three-pronged strategy: importing overseas products into China for co-development and global multi-center clinical trials; a global strategic collaboration with Hutchison China MedTech (HCM, Nasdaq) to develop four immune-disease candidate drugs with Inmagene leading global clinical development; and a ‘no-border innovation’ approach executing China-based, cost-efficient discovery programs with global IP. The company has launched innovative drug projects targeting 12 distinct targets. Inmagene operates full subsidiaries in both China and the United States. It has raised approximately $140 million in total financing to date and recently closed a $100 million Series C. Inmagene Biopharmaceuticals is a drug development company focused on immunology-related therapeutic areas and is led by Chairman and CEO Dr. Jonathan Wang. The company pursues a two-engine strategy: in-licensing clinical-stage foreign products that fit China and partnering to run global multi-center trials, and using China’s cost-efficient resources to develop best-in-class drug candidates. Inmagene has initiated four innovative programs targeting validated drug targets; its most advanced candidate, IMG-20, is about to enter global registration trials for multiple indications. The company intends to use new funds to conduct global clinical trials, advance R&D, and pursue product in-licensing activities. Financially, Inmagene has raised over $40M to date and recently closed a new financing to support its clinical and licensing plans.

Total raised

$121M

Funding rounds

2

Latest round

Series C

Latest activity

Jun 2021